99 related articles for article (PubMed ID: 20954701)
1. Identification of a novel type of CA19-9 carrier in human bile and sera of cancer patients: an implication of the involvement in nonsecretory exocytosis.
Uozumi N; Gao C; Yoshioka T; Nakano M; Moriwaki K; Nakagawa T; Masuda T; Tanabe M; Miyoshi E
J Proteome Res; 2010 Dec; 9(12):6345-53. PubMed ID: 20954701
[TBL] [Abstract][Full Text] [Related]
2. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
[TBL] [Abstract][Full Text] [Related]
4. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
6. Serum CA19-9 determination in the management of pancreatic cancer.
van den Bosch RP; van Eijck CH; Mulder PG; Jeekel J
Hepatogastroenterology; 1996; 43(9):710-3. PubMed ID: 8799418
[TBL] [Abstract][Full Text] [Related]
7. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
[TBL] [Abstract][Full Text] [Related]
8. Biomarker identification in human pancreatic cancer sera.
Hanas JS; Hocker JR; Cheung JY; Larabee JL; Lerner MR; Lightfoot SA; Morgan DL; Denson KD; Prejeant KC; Gusev Y; Smith BJ; Hanas RJ; Postier RG; Brackett DJ
Pancreas; 2008 Jan; 36(1):61-9. PubMed ID: 18192883
[TBL] [Abstract][Full Text] [Related]
9. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer.
Farina A; Dumonceau JM; Frossard JL; Hadengue A; Hochstrasser DF; Lescuyer P
J Proteome Res; 2009 Jan; 8(1):159-69. PubMed ID: 19055478
[TBL] [Abstract][Full Text] [Related]
11. Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels.
Hirano K; Kawa S; Oguchi H; Kobayashi T; Yonekura H; Ogata H; Homma T
J Natl Cancer Inst; 1987 Dec; 79(6):1261-8. PubMed ID: 2447318
[TBL] [Abstract][Full Text] [Related]
12. Immuno-histopathological correlations in exocrine pancreatic cancer.
Turculeanu A; Avrămescu C; Bălăşoiu M; Pleşea E; Simionescu C; Popescu CF
Rom J Morphol Embryol; 2005; 46(2):137-44. PubMed ID: 16287000
[TBL] [Abstract][Full Text] [Related]
13. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis.
Kumar Y; Gurusamy K; Pamecha V; Davidson BR
Pancreas; 2007 Aug; 35(2):114-9. PubMed ID: 17632316
[TBL] [Abstract][Full Text] [Related]
14. Establishment and characterization of human pancreatic adenocarcinoma cell line in tissue culture and the nude mouse.
Kong D; Nishino N; Shibusawa M; Kusano M
Tissue Cell; 2007 Aug; 39(4):217-23. PubMed ID: 17560620
[TBL] [Abstract][Full Text] [Related]
15. CA19-9: the Italian experience.
Gullo L
Pancreas; 1994 Nov; 9(6):717-9. PubMed ID: 7846014
[TBL] [Abstract][Full Text] [Related]
16. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
[TBL] [Abstract][Full Text] [Related]
17. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
18. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
19. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients.
Narimatsu H; Iwasaki H; Nakayama F; Ikehara Y; Kudo T; Nishihara S; Sugano K; Okura H; Fujita S; Hirohashi S
Cancer Res; 1998 Feb; 58(3):512-8. PubMed ID: 9458099
[TBL] [Abstract][Full Text] [Related]
20. Expression of tumor-associated carbohydrate antigens correlates with hepatic metastasis of pancreatic cancer: clinical and experimental studies.
Takamori H; Hiraoka T; Yamamoto T
Hepatogastroenterology; 1996; 43(9):748-55. PubMed ID: 8799425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
